Deep sequencing profiling of tumors
In one aspect of the present disclosure is a targeted sequencing workflow where an input sample comprising a sufficient quantity of genomic material is provided such minimal or no amplification cycles are utilized prior to sequencing.
1. A method of sequencing genomic material within at least one of tumor sample, a lymph node sample, or a blood sample comprising: (a) isolating between about 10 micrograms to about 250 micrograms of the genomic material from the at least one of the tumor sample, the lymph node sample, or the blood sample wherein the isolating of the genomic material comprises: (i) homogenizing the at least one of the tumor sample, the lymph node sample, or the blood sample to provide a homogenized sample, wherein any heterogeneity of cells within the at least one of the tumor sample, the lymph node, or the blood sample is substantially uniformly distributed within the at least the portion of the homogenized sample; (ii) lysing the cellular components within the homogenized sample to provide a lysed homogenized sample; and (iii) extracting genomic material from the lysed homogenized sample, wherein the extracted genomic material is representative of the nucleic acids present within the at least one of the tumor sample, the lymph node sample, or the blood sample, and wherein the extracted genomic material comprises target and non-target nucleic acid molecules; (b) enriching the extracted genomic material for target nucleic acid molecules, wherein the enriching provides between about 90 ng and about 900 ng of enriched genomic material; and (c) sequencing the enriched genomic material without performing post-capture amplification; and wherein no pre-capture amplification cycles are conducted prior to the sequencing of the captured genomic material.
2. The method of claim 1 , wherein between about 50 micrograms and about 100 micrograms of genomic material are isolated from the at least one of the tumor sample, the lymph node sample, or the blood sample.
3. A method of targeted representational sequencing comprising: (i) disassociating at least a portion of a tumor, one or more whole or partial lymph nodes, or any combination thereof to provide a homogenized sample, wherein any subpopulations of tumor cells that were originally spatially segregated within the tumor and/or the one or more whole or partial lymph nodes are distributed throughout the homogenized sample; (ii) lysing the cellular components within the homogenized sample to provide a lysed homogenized sample; (iii) extracting between about 10 micrograms to about 100 micrograms of genomic material from the —lysed homogenized sample, wherein the extracted genomic material comprises target and non-target nucleic acid molecules; (iv) enriching the extracted genomic material for target nucleic acid molecules to provide between about 90 ng to about 900 ng of enriched genomic material; and (v) sequencing the enriched genomic material without performing post-capture amplification, wherein no pre-capture amplification cycles are conducted prior to the sequencing of the captured genomic material.
4. A method of reducing PCR-introduced mutations during sequencing comprising: isolating between about 10 micrograms to about 100 micrograms of DNA from a homogenized sample, wherein the homogenized sample substantially expresses a heterogeneity of cells of a tumor sample or lymph node sample from which the homogenized sample was derived; enriching the isolated DNA for target nucleic acid molecules, wherein an amount of enriched isolated DNA ranges from between about 90 ng to about 900 ng; and sequencing the enriched isolated DNA without performing post-capture amplification, and wherein no pre-capture amplification cycles are performed on the prepared isolated DNA prior to sequencing.
5. The method of claim 4 , wherein the sample is derived from a patient suspected of having cancer.
6. The method of claim 4 , wherein the sample is derived from a patient diagnosed with cancer.
7. The method of claim 4 , wherein the sample is derived from a patient at risk of developing cancer.
8. The method of claim 4 , wherein the sample is derived from healthy tissue samples.
9. The method of claim 1 , wherein the sample comprises at least 1,500,000 cells.
10. The method of claim 3 , wherein the sample comprises at least 1,500,000 cells.
11. The method of claim 4 , wherein the sample comprises at least 1,500,000 cells.
12. The method of claim 1 , wherein the enriching of the extracted genomic material for target nucleic acid molecules comprises: (i) hybridizing the extracted genomic material to probes to capture the target nucleic acid molecules within the extracted genomic material; (ii) removing non-target nucleic acids; and (iii) releasing the enriched extracted genomic material from the probes.
13. The method of claim 1 , wherein the homogenization comprises mechanical shearing.
14. The method of claim 1 , wherein the sequencing comprises next generation sequencing.
15. The method of claim 3 , wherein the enriching of the extracted genomic material for target nucleic acid molecules comprises: (i) hybridizing the extracted genomic material to probes to capture the target nucleic acid molecules within the extracted genomic material; (ii) removing non-target nucleic acids; and (iii) releasing the enriched extracted genomic material from the probes.
16. The method of claim 3 , wherein the dissociation comprises mechanical shearing.
17. The method of claim 3 , wherein the sequencing comprises next generation sequencing.
18. The method of claim 4 , wherein the enriching of the isolated DNA for target nucleic acid molecules comprises: (i) hybridizing the extracted genomic material to probes to capture the target nucleic acid molecules within the extracted genomic material;
(ii) removing non-target nucleic acids; and (iii) releasing the enriched isolated DNA from the probes.
19. The method of claim 4 , wherein the sequencing comprises next generation sequencing.